Pharvaris N.V. (PHVS)
USD 18.5
(0.05%)
USD 18.5
(0.05%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -91.14 Million | -67.16 Million | -44.59 Million | -21.49 Million | -6.67 Million | -3.91 Million |
| Net Income | -98.8 Million | -75.65 Million | -42.66 Million | -26.06 Million | -8.02 Million | -4.31 Million |
| Depreciation & Amortization | 252.27 Thousand | 152.94 Thousand | 77.37 Thousand | 7401.00 | 549.00 | - |
| Deferred income taxes | -15.29 Million | - | -12.05 Million | 1.3 Million | - | - |
| Stock-based compensation | 10.66 Thousand | 11.34 Million | 8.19 Million | 1.58 Million | 116.14 Thousand | 100.74 Thousand |
| Change in working capital | -5.74 Million | 8.37 Million | 1.57 Million | 1.57 Million | 1.23 Million | 291.54 Thousand |
| Other non-cash items | 17.78 Million | -11.38 Million | 267.7 Thousand | 98.67 Thousand | -3693.00 | 2969.00 |
| Investing Cash Flow | -88.13 Thousand | -124.29 Thousand | -130.03 Thousand | -42.97 Thousand | -13.47 Thousand | - |
| Investments in PPE | -88.13 Thousand | -124.29 Thousand | -130.03 Thousand | -42.97 Thousand | -13.47 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 318.72 Million | 8.65 Million | 143.67 Million | 101.2 Million | 21.63 Million | 4.5 Million |
| Debt repayment | -220.5 Thousand | -119.52 Thousand | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 318.93 Million | 9.6 Million | 156.82 Million | 102.51 Million | 22.46 Million | 4.5 Million |
| Other Financing Activities | -17.29 Million | -839.97 Thousand | -13.15 Million | -1.31 Million | -836.18 Thousand | 4508.85 |
| Accounts receivables | -40.2 Thousand | 311.89 Thousand | -135.7 Thousand | -358.74 | -208.72 Thousand | -49.52 Thousand |
| Accounts payables | -4.08 Million | 3.83 Million | 1.72 Million | - | 273.68 Thousand | 188.45 Thousand |
| Inventory | -1.00 | 150.87 Thousand | -62.84 Thousand | - | 3583.00 | - |
| Other working capital | -1.61 Million | 4.07 Million | 44.84 Thousand | 1.57 Million | 1.16 Million | 161.95 Thousand |
| Cash at beginning of period | 161.38 Million | 209.35 Million | 98.62 Million | 20.32 Million | 5.38 Million | 4.79 Million |
| Cash at end of period | 391.55 Million | 161.83 Million | 209.35 Million | 98.62 Million | 20.32 Million | 5.38 Million |
| Capital Expenditure | -88.13 Thousand | -124.29 Thousand | -130.03 Thousand | -42.97 Thousand | -13.47 Thousand | - |
| Effect of forex changes on cash | -2.85 Million | 11.12 Million | 11.78 Million | -1.35 Million | - | - |
| Net cash flow / Change in cash | 230.17 Million | -47.51 Million | 110.72 Million | 78.3 Million | 14.94 Million | 590.19 Thousand |
| Free Cash Flow | -91.22 Million | -67.28 Million | -44.72 Million | -21.54 Million | -6.69 Million | -3.91 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -29.88 Million | -27.73 Million | -98.8 Million | -31.9 Million | -23.45 Million | -21.8 Million |
| Depreciation & Amortization | 69.02 Thousand | 66.35 Thousand | 252.27 Thousand | 64.33 Thousand | 67.93 Thousand | 61.72 Thousand |
| Deferred income taxes | - | - | -15.29 Million | -4.56 Million | -3.1 Million | -1.01 Million |
| Stock-based compensation | 3887.44 | 2.4 Million | 10.66 Million | 2.47 Million | 2.88 Million | 2.71 Million |
| Change in working capital | 1.72 Million | 1.63 Million | -5.74 Million | 1.34 Million | 113.97 Thousand | -454.35 Thousand |
| Other non-cash items | 3.38 Million | -55.96 Thousand | 17.78 Million | 10.16 Million | -61.74 Thousand | 16.04 Thousand |
| Investing Cash Flow | -40.08 Thousand | -30.7 Thousand | -88.13 Thousand | -26.95 Thousand | -7490.00 | -35.07 Thousand |
| Investments in PPE | -40.08 Thousand | -30.7 Thousand | -88.13 Thousand | -26.95 Thousand | -7490.00 | -35.07 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 318.51 Thousand | 795.04 Thousand | 318.72 Million | 254.29 Million | -122.33 Thousand | 63.84 Million |
| Debt repayment | -53.47 Thousand | -53.76 Thousand | -220.5 Thousand | -54.65 Thousand | -75.6 Thousand | -33.49 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 371.82 Thousand | 189.76 Thousand | 318.93 Million | 254.35 Million | 116.05 Thousand | 64.08 Million |
| Other Financing Activities | -66.07 Thousand | 659.03 Thousand | -17.29 Million | -16.92 Million | -162.78 Thousand | -210.47 Thousand |
| Accounts receivables | -153.5 Thousand | 60.45 | -40.2 Thousand | -112.55 Thousand | 26.17 Thousand | 59.48 Thousand |
| Accounts payables | -2.62 Million | 2.66 Million | -4.08 Million | -1.84 Million | -748.34 Thousand | -2.71 Million |
| Inventory | - | - | -1.00 | - | -6787.00 | 95.35 Thousand |
| Other working capital | 4.49 Million | -1077.55 | -1.61 Million | 3.3 Million | 842.92 Thousand | 2.1 Million |
| Cash at beginning of period | 368.68 Million | 391.23 Million | 161.38 Million | 158.6 Million | 179.18 Million | 135.18 Million |
| Cash at end of period | 343.77 Million | 368.34 Million | 391.55 Million | 391.55 Million | 158.35 Million | 179.18 Million |
| Capital Expenditure | -40.08 Thousand | -30.7 Thousand | -88.13 Thousand | -26.95 Thousand | -7490.00 | -35.07 Thousand |
| Effect of forex changes on cash | 2.63 Million | 578 Thousand | -2.85 Million | -5.02 Million | 2.85 Million | 684.3 Thousand |
| Net cash flow / Change in cash | -24.9 Million | -22.88 Million | 230.17 Million | 232.94 Million | -20.83 Million | 44 Million |
| Free Cash Flow | -27.66 Million | -24.26 Million | -91.22 Million | -22.44 Million | -23.56 Million | -20.51 Million |
TI
LXCHEM
RXMD
RY4C
DOM
MAXHEALTH